Holen Sie sich die Stockscreener-App
0.3857
0.87%
-0.0056
Handel nachbörslich:
.37
-0.0157
-4.07%
Schlusskurs vom Vortag:
$0.3801
Offen:
$0.3721
24-Stunden-Volumen:
17,518
Relative Volume:
0.09
Marktkapitalisierung:
$8.79M
Einnahmen:
$81.89M
Nettoeinkommen (Verlust:
$-55.20M
KGV:
-0.1431
EPS:
-2.6959
Netto-Cashflow:
$-67.40M
1W Leistung:
-3.04%
1M Leistung:
-17.39%
6M Leistung:
-45.98%
1J Leistung:
-91.72%
1-Tages-Spanne:
$0.3702
$0.3995
1-Wochen-Bereich:
$0.3689
$0.4195
52-Wochen-Spanne:
$0.365
$4.97
Turnstone Biologics Corp Stock (TSBX) Company Profile
Firmenname
Turnstone Biologics Corp
Sektor
Branche
Telefon
347-897-5988
Adresse
9310 ATHENA CIRCLE, SUITE 300, LA JOLLA
Vergleichen Sie TSBX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TSBX
Turnstone Biologics Corp
|
0.3857 | 8.79M | 81.89M | -55.20M | -67.40M | -2.6959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Turnstone Biologics Corp Stock (TSBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-11-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-10-14 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-08-16 | Eingeleitet | SVB Securities | Market Perform |
| 2023-08-15 | Eingeleitet | BofA Securities | Buy |
| 2023-08-15 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Turnstone Biologics Corp Aktie (TSBX) Neueste Nachrichten
Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering, Business Wires News - AsiaOne
Turnstone Biologics stock plunges to 52-week low of $0.4 - MSN
Turnstone Biologics stock plunges to 52-week low of $0.4 By Investing.com - Investing.com Canada
Cautious Hold on Turnstone Biologics Amid TIL Therapy Challenges and Strategic Alternatives - TipRanks
Analysts Offer Predictions for TSBX FY2024 Earnings - Defense World
Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Leerink Partnrs Weighs in on TSBX FY2024 Earnings - Armenian Reporter
Turnstone Biologics (NASDAQ:TSBX) Stock Rating Lowered by Piper Sandler - Defense World
Turnstone Biologics halts TIDAL-01 development, seeks alternatives - MSN
A Look at Turnstone Biologics Corp (TSBX) Shares in the Recent Past Indicates Growth - SETE News
TSBX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Turnstone Biologics to explore strategic alternatives - The Pharma Letter
Piper Sandler Downgrades Turnstone Biologics to Neutral From Overweight, Adjusts Price Target to $0.40 From $3.75 - Marketscreener.com
Turnstone Biologics Corp (NASDAQ: TSBX) Stock’s Potential for Success in the Coming Months - Marketing Sentinel
Piper Sandler cuts Turnstone Biologics stock rating to neutral - MSN
Turnstone Biologics halts TIDAL-01 development, seeks alternatives By Investing.com - Investing.com South Africa
TSBX’s price-to-book ratio: An indicator of the company’s performance - US Post News
Turnstone Biologics Stops Tidal-01 Trials, Explores Strategic Alternatives; Shares Rise - Marketscreener.com
Turnstone Biologics Halts TIDAL-01 Studies Amid Market Woes - TipRanks
Turnstone Biologics Announces Plans to Explore Strategic Alternatives - The Manila Times
Turnstone Biologics Corp. Discontinues TIDAL-01 Clinical Studies and Initiates Strategic Alternatives Review - Nasdaq
Scailyte Announces Collaboration With Turnstone Biologics to Identify Biomarker Signatures in Solid Tumors With TIL Therapy - ACCESS Newswire
Head to Head Survey: Turnstone Biologics (NASDAQ:TSBX) & Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) - Defense World
Reviewing AlloVir (NASDAQ:ALVR) and Turnstone Biologics (NASDAQ:TSBX) - Defense World
Turnstone Biologics (NASDAQ:TSBX) Stock Price Down 9.1% – Time to Sell? - Defense World
Fmr LLC Boosts Stock Position in Turnstone Biologics Corp. (NASDAQ:TSBX) - Defense World
Turnstone Biologics stock plunges to 52-week low of $0.44 By Investing.com - Investing.com Australia
Turnstone Biologics stock plunges to 52-week low of $0.44 - Investing.com
Turnstone Biologics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Turnstone Biologics stock downgraded amid concerns over therapy scalability and funding - Investing.com
Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights - The Manila Times
Turnstone Biologics Faces Financial and Operational Challenges - TipRanks
Turnstone Biologics Reports 25% Response Rate in Cancer Trial, Extends Cash Runway to 2026 | TSBX Stock News - StockTitan
Turnstone advances TIL therapy for solid tumors at SITC meeting By Investing.com - Investing.com Australia
Turnstone advances TIL therapy for solid tumors at SITC meeting - Investing.com
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting - The Manila Times
Turnstone Biologics Reveals Breakthrough TIL Cancer Treatment Data at SITC 2024 | TSBX Stock News - StockTitan
Warning: TSBX is at high risk of performing badly - MSN
Turnstone Biologics (NASDAQ:TSBX) & Recursion Pharmaceuticals (NASDAQ:RXRX) Critical Contrast - Defense World
BofA downgrades Turnstone stock, citing wait-and-see approach until 2025 data - Investing.com
Turnstone fires most staff in bid to to extend runway - The Pharma Letter
Turnstone Biologics Streamlines Operations and Leadership - Yahoo Finance
Turnstone Biologics announces strategic cuts and focus shift - Investing.com
Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway - ForexTV.com
Turnstone lays off 60% of staff, shakes up C-suite to keep cancer cell therapy on track - Fierce Biotech
Turnstone Biologics stock plunges to 52-week low of $0.45 - Investing.com
Finanzdaten der Turnstone Biologics Corp-Aktie (TSBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.95%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):